d-9

TrxR-IN-D9 is a novel inhibitor of thioredoxin reductase (TrxR).

L-838417-D9 is a novel deuterated subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes[1].

Febuxostat-D9 is deuterium labeled Febuxostat (TMSM-3473), which is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.

Nadolol-D9 is a deuterated analog of Nadolol (TMSM-1693), whose parent compound nadolol is an orally active, non-selective β-adrenergic receptor blocker.

Valsartan-D9 is a deuterium-labeled valsartan. Valsartan (T6716) is an antagonist of the angiotensin II receptor and for the treatment of high blood pressure and heart failure.

Desbutyl Lumefantrine-D9, a deuterium-labeled metabolite of Lumefantrine, exhibits the incorporation of deuterium atoms.

Ivacaftor-D9 is transmembrane conductance regulator (CFTR) channel activator, is used potentially for the treatment of cystic fibrosis.

Methyl-D9-choline is an isotopically labeled choline tracer.

Choline-D9 chloride is a deuterium-labelled derivative of choline chloride (TMSM-3273) for isotope tracing. Choline chloride, an essential nutrient, activates α7 nicotinic acetylcholine receptors and exhibits anti-inflammatory and analgesic properties.

2-(5-tert-Butyl-2-hydroxyphenyl) benzotriazole-D9 is the deuterated form of 2- (2H-Benzo[d][1,2,3]triazol-2-yl)-4- (tert-butyl)phenol.

SD-254 is a deuterium analog of Effexor, with fewer side effects and a longer half-life.

C-Met inhibitor D9 is a c-Met kinase inhibitor.

MDL-27048 is a powerful and reversible microtubule inhibitor.

Guaifenesin-D3 is intended for use as an internal standard for the quantification of guaifenesin by GC- or LC-MS. Guaifenesin (T0739) is an expectorant. It inhibits production of mucin 5AC (MUC5AC), reduces mucus viscosity and elasticity, and increases the mucociliary transport rate of endogenous particles in primary human tracheobronchial epithelial cells in a concentration-dependent manner. Guaifenesin (T0739) increases phenol red secretion, a marker of expectorant activity, in rats.3 Formulations containing guaifenesin have been used as expectorants in the treatment of the common cold and chronic bronchitis.

Phenylbutazone-D9 is intended for use as an internal standard for the quantification of phenylbutazone by GC- or LC-MS. Phenylbutazone (T1432) is a non-steroidal anti-inflammatory drug and an inhibitor of the peroxidase activity of COX (IC50 = ~100 µM in the presence of hydrogen peroxide). It also inhibits prostaglandin I synthase (IC50 = ~25 µM in the presence of hydrogen peroxide). Phenylbutazone (T1432) (2 mg/kg) reduces increases in type II collagen levels in the inflamed joints of an equine model of LPS-induced acute synovitis. Formulations containing phenylbutazone have been used in the treatment of lameness in horses.

G-33378 is a metabolite of sulfinpyrazone that inhibits human platelet cyclo-oxygenase activity.

1,3,7-Trimethyluric Acid-D9 is intended for use as an internal standard for the quantification of 1,3,7-Trimethyluric Acid (T19792) by GC- or LC-MS. 1,3,7-Trimethyluric acid is a derivative of uric acid and a metabolite of caffeine. It is formed from caffeine by the cytochrome P450 isoform CYP3A4. 1,3,7-Trimethyluric acid scavenges hydroxyl radicals in a cell-free assay and inhibits t-butyl hydroperoxide-induced lipid peroxidation by 56.5% in isolated human erythrocyte membranes.

hClpP-activator-D9 is a novel potent and species-selective activator of human ClpP (hClpP).

Miglustat-D9 hydrochloride, a deuterium-labeled variant of Miglustat (hydrochloride), functions as a glucosylceramide synthase inhibitor. Its primary application is in the treatment of Type I Gaucher disease (GD1) [1][2].

1-Palmitoyl-D9-2-hydroxy-sn-glycero-3-PA is compound, an analog of LPA with palmitic acid at the sn-1 position, activates reporter gene expression in PC12 cells fitted with human lysophosphatidic acid receptor 4 (LPA4) at 0.01 to 10 µM concentrations. Additionally, 1-palmitoyl LPA prompts aggregation in isolated human platelets within the 12-300 µM range, a process reversible by prostaglandin E1 (PGE1), theophylline, or EDTA. It also interacts with calcium and magnesium to boost the efficacy of ampicillin, piperacillin, and ceftazidime against P. aeruginosa strains from cystic fibrosis patients.

1-1(Z)-Hexadecenyl-2-Palmitoyl-D9-sn-glycero-3-PE is a plasmalogen incorporating 1 (Z)-hexadecanoic acid and palmitic acid at the sn-1 and sn-2 positions respectively, in analyses performed using GC- or LC-MS.

1-Palmitoyl-D9-2-Palmitoyl-sn-glycero-3-PE is essential in the inner plasma membrane leaflet. This compound forms a condensed lipid monolayer with cholesterol through tight hydrogen bonding between 1,2-DPPE headgroups, enhancing membrane fluidity to support transport and signaling.

1-Palmitoyl-D9-2-hydroxy-sn-glycero-3-PE serves as an internal standard for quantifying 1-palmitoyl-2-hydroxy-sn-glycero-3-PE, a lysophospholipid naturally found to inhibit L. donovani promastigotes growth (GI50= 8 µM). Its levels are reduced in mice after alcohol-induced liver damage, in hepatocellular carcinoma mouse xenografts, and in humans following a rigorous three-day exercise regimen of 2.5 hours running daily and 14 hours post-regimen. This compound is also applied in measuring saturated lysophosphoethanolamines, highlighting its broad utility in biochemical research and disease model studies.

1-Palmitoyl-D9-2-Palmitoyl-sn-glycerol is diacylglycerol, featuring palmitic acid at both the sn-1 and sn-2 positions, stimulates protein kinase C (PKC) activity by 15% at a 25 μM concentration. Additionally, 1,2-dipalmitoyl-sn-glycerol encourages rapid growth in Frankia, a genus of Gram-positive bacteria.